FDA 批准 Kite 的生产工艺变更，将 Yescarta® CAR T 细胞疗法的周转时间从 16 天缩短至 14 天。 FDA approves Kite's manufacturing process change, reducing Yescarta® CAR T-cell therapy turnaround time from 16 to 14 days.

吉利德 (Gilead) 旗下公司 Kite 的生产工艺变更已获得美国食品和药物管理局 (FDA) 的批准，该变更可缩短其 Yescarta® CAR T 细胞疗法的中位周转时间。 Kite, a Gilead company, has received approval from the U.S. Food and Drug Administration (FDA) for a manufacturing process change that reduces the median turnaround time for its Yescarta® CAR T-cell therapy. 此次批准将 Yescarta 的生产时间从 16 天缩短至 14 天，改善了复发或难治性大 B 细胞淋巴瘤患者的治疗机会。 The approval shortens the production time for Yescarta from 16 days to 14 days, improving access to the treatment for patients with relapsed or refractory large B-cell lymphoma.